| Opis |
This up-to-date and important conference has been organized by Professor Artur Jurczyszyn of the Jagiellonian University Medical College in Krakow, Poland.
There will be a Welcome Dinner on Friday, September 6, 2024, at 7:00 p.m. at Kopiec Kosciuszki.
Professors Tomasz Grodzicki and Artur Jurczyszyn will open the conference at 12:00 p.m. on Saturday, September 7, 2024.
The chairmen of Session I consist of Professors Wiesław W. Jędrzejczak, Lidia Usnarska-Zubkiewicz, and Piotr Rzepecki.
The first speaker is Professor Surbhi Sidana, Stanford University, USA, on “CAR-T Cell Therapy in Multiple Myeloma: Current Limitations and Potential Strategies.”
Professor Vaishali Sanchorowala, Boston Medical Center, USA, will follow with a presentation on “Advances in Systemic AL Amyloidosis.”
Professor Gabor Mikala, National Institute for Hematology and Infectious Disease, Hungary, will present an address entitled “The Importance of Metabolism in Long-Term Myeloma Care.”
Professor David H. Vesole, Hackensack University Medical Center, New Jersey Medical School, Rutgers University, New Jersey, USA, with a presentation “T-cell Redirecting Antibody in Patients with Relapsed or Refractory Multiple Myeloma.”
Following the coffee break, the chairmen of Session II are Professors Aleksander B. Skotnicki, Boguslaw Machalinski, and Jacek Roliński.
The first presentation of Session II is Professor Ramon Garcia-Sanz, Department of Hematology, University Hospital of Salamanca, Salamanca, Spain, who will speak on “Minimal Residual Disease in Multiple Myeloma: Past, Present and Future.”
This will be followed by a presentation by Professor Elena Zamagni, Universita di Bologna, Bologna, Italy, “How I Treat High-Risk Multiple Myeloma.”
The afternoon session will close with “Supportive Care in Multiple Myeloma in 2024” by the host, Professor Artur Jurczyszyn.
Of note, there will be a 10-minute discussion after each lecture.
The sessions will be followed by a dinner at Restaurant Hotel Estera at 6:00 p.m.
This conference will update the attendees on CAR-T Cell Therapy in Multiple Myeloma: Current Limitations and Potential Strategies, Advances in Systemic AL Amyloidosis, The Importance of Metabolism in Long-Term Myeloma Care, T-cell Redirecting Antibody in Patients with Relapsed or Refractory Multiple Myeloma, Minimal Residual Disease in Multiple Myeloma: Past, Present and Future, How I Treat High-Risk Multiple Myeloma, and Supportive Care in Multiple Myeloma in 2024.
Robert A. Kyle, MD, MACP
Professor of Medicine
Emeritus, Retired – 2023
Mayo Clinic
Rochester, MN
Zapraszamy do zapoznania się ze szczegółami Konferencji na stronie wydarzenia. |
